Clinical Trials Logo

Filter by:
NCT ID: NCT00439777 Completed - Pulmonary Embolism Clinical Trials

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Start date: March 2007
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic Deep-Vein Thrombosis (DVT) (Einstein-PE).

NCT ID: NCT00439725 Completed - Clinical trials for Venous Thromboembolism

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Start date: February 2007
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (deep vein thrombosis) or PE (pulmonary embolism) who completed 6 or 12 months of treatment with rivaroxaban or VKA (vitamin K antagonist) are eligible for this trial (Einstein-Extension study).

NCT ID: NCT00439647 Completed - Male Osteoporosis Clinical Trials

Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis

Start date: December 2006
Phase: Phase 3
Study type: Interventional

This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.

NCT ID: NCT00439192 Terminated - Clinical trials for Urinary Incontinence

ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

Start date: February 2007
Phase: Phase 2
Study type: Interventional

This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo , when administered to patients with OAB and to compare the efficacy of escalating doses of ELB245 versus the standard treatment tolterodine, when administered to patients with OAB.

NCT ID: NCT00437645 Completed - Clinical trials for Essential Hypertension

Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension

Start date: January 2007
Phase: Phase 3
Study type: Interventional

This study was designed to compare the efficacy, tolerability, and safety of the combination valsartan/amlodipine 160/5 mg versus amlodipine 10 mg in patients with essential hypertension not adequately controlled (defined as mean sitting systolic blood pressure [msSBP] ≥ 130 mmHg and ≤ 160 mmHg) on amlodipine 5 mg alone. The study evaluated both the efficacy and tolerability of the treatments by providing data that assessed blood pressure and the proportion of patients developing peripheral edema.

NCT ID: NCT00437138 Completed - Clinical trials for Coronary Heart Disease

Controlled Exposures to Air Pollution in Patients With Coronary Heart Disease

Start date: April 2006
Phase: Phase 0
Study type: Interventional

Air pollution is a major cause of cardiovascular morbidity and mortality. The components of air pollution responsible and the mechanisms through which they might mediate these harmful effects remain only partially understood. We hypothesise that these adverse effects are mediated by combustion derived air pollutants and that even a brief exposure will effect heart and blood vessel function. We assess the effect of dilute diesel exhaust inhalation at levels encountered in urban road traffic on heart and blood vessel function in patients with stable coronary heart disease.

NCT ID: NCT00437073 Terminated - Neoplasms, Breast Clinical Trials

Brain Metastases In ErbB2-Positive Breast Cancer

Start date: May 2007
Phase: Phase 2
Study type: Interventional

This study is for patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. The study will determine how safe and effective lapatinib is when given in combination with capecitabine to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed regularly during the course of the study.

NCT ID: NCT00436982 Completed - Clinical trials for Arthroplasty, Replacement, Knee

Evaluation of Triathlon - a New Total Knee Prosthesis System - Triathlon vs. Duracon

Start date: February 2006
Phase: N/A
Study type: Interventional

The objective is to investigate the Clinical, Radiographic, Roentgen Stereophotogrammetric behaviour and patient outcome when using the Triathlon total knee prosthesis in a prospective randomized clinical trial.

NCT ID: NCT00436033 Completed - Clinical trials for Fibromyalgia Syndrome

A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome

Start date: February 2006
Phase: Phase 3
Study type: Interventional

Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.

NCT ID: NCT00435981 Completed - Type 1 Diabetes Clinical Trials

Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes

Start date: January 2005
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta cell function in children and adolescents with type 1 diabetes with a diabetes duration less than 18 months at intervention.